PF-Atlas › Clinical Trials › NCT06383819
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
Longidaza® · Phase 3
Registry ID
NCT06383819
Phase
Phase 3
Status
Completed
Drug / intervention
Longidaza®
Sponsor
NPO Petrovax
Start
2022-04-08
Enrollment
392
Locations
30
About this trial
The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06383819 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.